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Abstract
Background: Dimethylarginine dimethylaminohydrolase 2 (DDAH2) regulates the synthesis of nitric oxide (NO)
through the metabolism of the endogenous inhibitor of nitric oxide synthase, asymmetric dimethylarginine (ADMA).
Pilot studies have associated the rs805305 SNP of DDAH2 with ADMA concentrations in sepsis. This study explored
the impact of the rs805305 polymorphism on DDAH activity and outcome in septic shock.
Methods: We undertook a secondary analysis of data and samples collected during the Vasopressin versus
noradrenaline as initial therapy in septic shock (VANISH) trial. Plasma and DNA samples isolated from 286
patients recruited into the VANISH trial were analysed. Concentrations of L-Arginine and the methylarginines
ADMA and symmetric dimethylarginine (SDMA) were determined from plasma samples. Whole blood and
buffy-coat samples were genotyped for polymorphisms of DDAH2. Clinical data collected during the study
were used to explore the relationship between circulating methylarginines, genotype and outcome.
Results: Peak ADMA concentration over the study period was associated with a hazard ratio for death at 28
days of 3.3 (95% CI 2.0–5.4), p < 0.001. Reduced DDAH activity measured by an elevated ADMA:SDMA ratio
was associated with a reduced risk of death in septic shock (p = 0.03). The rs805305 polymorphism of DDAH2
was associated with reduced DDAH activity (p = 0.004) and 28-day mortality (p = 0.02). Mean SOFA score and
shock duration were also reduced in the less common G:G genotype compared to heterozygotes and C:C genotype
patients (p = 0.04 and p = 0.02, respectively).
Conclusions: Plasma ADMA is a biomarker of outcome in septic shock, and reduced DDAH activity is associated with a
protective effect. The polymorphism rs805305 SNP is associated with reduced mortality, which is potentially mediated
by reduced DDAH2 activity.
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Background
Sepsis arises when an infective organism provokes a
series of host responses, the dysregulation of which leads
to organ dysfunction. There is a spectrum of disease
which, at its most severe, is characterised by cellular, tis-
sue, vascular and cardiac abnormalities [1, 2]. Collect-
ively these pathological changes lead to altered cellular
metabolic function, impaired tissue oxygen availability
and reduced utilisation by the tissues [3–6]. Sepsis is a
major health challenge in both the developing and the
developed world, with more than 2 million cases in the
USA [7] and an estimated 5.3 million deaths worldwide
[8] each year.
Nitric oxide (NO) is a critical mediator of the vascular,
immune and cardiac response to infection [3, 9–12]. NO
is synthesised by the three isoforms of nitric oxide syn-
thase (NOS) in a process that is tightly regulated at
every stage from gene expression to substrate and
co-factor availability [13]. The discovery of a family of
arginine derivatives, known as the methylarginines
(MA), which act as inhibitors by competing with the
binding of L-arginine to the active site of the NOS en-
zyme, is one of few examples where an enzyme system is
regulated by endogenous competitive inhibition [14].
Three MA subtypes have been identified in mammals,
asymmetric dimethylarginine (ADMA), symmetric
dimethylarginine (SDMA) and monomethylarginine
(L-NMMA) [15]. Within the cell, both ADMA and
L-NMMA act through competitive inhibition of
L-arginine binding to the NOS enzymes (Fig. 1).
L-NMMA and ADMA are equipotent but L-NMMA is
present at only around 10% of the concentration of
ADMA in most tissues and so plays a lesser role in the
regulation of NOS activity [16]. By contrast, SDMA
does not compete with L-arginine at physiological and
pathophysiological concentrations and has no apparent
impact on NOS activity. Elevation of plasma ADMA
concentration has been associated with risk in cardiac
[17] and chronic renal disease [18]. In sepsis, a number
of studies in heterogeneous clinical populations have
suggested that plasma ADMA concentration is associ-
ated with illness severity and death [19–23].
Within the cell, ADMA is tightly regulated by the two
isoforms of dimethylarginine dimethylaminohydrolase
(DDAH1 and DDAH2) that hydrolyse the two active
methylarginines to methylamines and L-citrulline [24,
25]. Only around 10% of ADMA is cleared by the kidney
in normal conditions [26]. In contrast, SDMA is not
metabolised by DDAH and is largely cleared by the
kidney. The two isoforms of DDAH have similar
structure but arise from different genetic loci and are
expressed in differing tissue distributions [24]. SNPs
of the DDAH2 gene have been associated with disease
severity and/or progression in a number of disease
states including hypertension [27], myocardial infarc-
tion [28] and chronic renal failure [29].
The production of NO in sepsis is regulated by a num-
ber of different processes in addition to the level of ex-
pression of NOS isoforms. These include changes in
substrate and co-factor bioavailability, and cellular con-
centrations of ADMA, which competes with L-arginine
binding to the NOS isoforms to regulate NO production.
ADMA concentrations are regulated by the DDAH en-
zymes and their expression in different tissues may sug-
gest differential roles in regulating the inflammatory
response. The DDAH2 gene is located in the major
histocompatibility complex (MHC)III region of chromo-
some 6 and DDAH2 is the only isoform found in im-
mune cells [24]; DDAH1 by contrast, the gene that is
found on chromosome 1, is an important regulator of
vascular function and has been shown to modulate the
haemodynamic response in animal models of sepsis [30,
31]. These observations have led to the suggestion that
DDAH2-mediated regulation of ADMA concentration
may play a role in NO mediated inflammatory condi-
tions [32] such as septic shock.
We undertook a secondary analysis of samples and clin-
ical data from the Vasopressin versus noradrenaline as ini-
tial therapy in septic shock (VANISH) trial, which was a
randomised controlled trial of two vasoactive treatments
in septic shock. Our study tested the hypothesis that
ADMA has a mechanistic role in determining outcome
from septic shock and that the polymorphism of the
DDAH2 promoter (rs805305) may impact on methylargi-
nine metabolism and outcome in these patients.
Methods
In the VANISH trial, adult patients with septic shock,
from 18 centres in the UK were recruited within a max-
imum of 6 h after the onset of hypotension to participate
in a double-blind randomised controlled trial of vaso-
pressin versus norepinephrine as the first-line treatment
of vasopressor-dependent septic shock. The study was a
2 × 2 design with patients in each group randomised to
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receive placebo or hydrocortisone in addition to their pri-
mary intervention drug in the event that they did not re-
spond adequately to study drug monotherapy. The study
received ethics committee approval (Oxford A research
ethics committee (12/SC/0014)) and was registered prior
to the start of recruitment (ISRCTN20769191). Extensive
clinical data were collected at baseline and on a daily basis
up to day 28 after randomisation. The detailed protocol
for this study and the primary outcome has been pub-
lished previously [33, 34].
In 16 of the participating centres, local research teams
were able to collect serial blood samples for subsequent
analysis. Samples were collected at up to four time
points during the study, after randomisation but prior to
starting study drug (time point 0), and on study days 3,
5 and 7 thereafter.
Whole blood was collected in a 10-ml EDTA tube and
immediately stored on ice. Within 15 min of sampling,
the tube underwent centrifugation at 1000 g for 10 min.
At the end of this period, plasma and buffy-coat aliquots
were collected in separate cryotubes, labelled appropri-
ately and immediately stored at − 80 °C. If staffing levels
out of hours prevented sample processing, whole blood
was stored for subsequent DNA analysis only.
Samples were analysed en bloc at the end of the study
period. Methylarginine and L-arginine concentrations were
analysed using an established high-performance liquid
chromatography mass spectrometry approach [30, 35, 36].
In brief, samples were defrosted on ice and a 100-μL ali-
quot of plasma was collected and a known concentration of
deuterium-labelled [7] ADMA standard was added. Follow-
ing protein precipitation with methanol, the solution
underwent centrifugation at 16000 rcf for 10min. The
supernatant was then dried and the residue re-suspended
in mobile phase (0.1% formic acid) for analysis. A standard
curve of ADMA, SDMA and L-arginine samples of 10
known concentrations was prepared (0–10 μM).
The presence of the rs805305 SNP in the DDAH2 gene
was determined using genomic DNA extraction from
buffy coat and whole blood samples by LGC group (Hert-
fordshire, UK). In a parallel experiment, the genotype of
eight polymorphisms of the DDAH1 gene was also deter-
mined (Additional file 1: Table S5). Genotyping was
undertaken using a proprietary competitive allele-specific
Fig. 1 Representative image of the synthesis and regulation of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) in
sepsis. Protein arginine methyl transferases (PRMT) catalyse the methylation of arginine containing protein residues to ADMA and SDMA, which
are released upon proteolysis. ADMA and SDMA are transported via the y+ cationic amino acid transporter into and out of the circulation. SDMA
is not metabolised in most cell,s whereas ADMA is metabolised by the two isoforms of dimethylarginine dimethylaminohydrolase (DDAH) in a
wide range of tissues. ADMA acts intracellularly to inhibit nitric oxide synthase (NOS), SDMA has no action on NOS isoforms. SDMA is cleared by
the kidney largely unchanged and in small part through metabolism by AGXT2 (not shown). ADMA is largely metabolised by DDAH to dimethylamine
(DMA); a small amount is cleared unchanged through the kidney. In sepsis, the synthesis of ADMA and SDMA may be increased through high protein-
turnover in patients in a catabolic state and reduced renal clearance as a consequence of acute kidney injury. Differences in the relative concentrations
of these methylarginines reflect their differential metabolism by DDAH isoforms as only ADMA is a DDAH substrate. Note, monomethylarginine (L-NMMA)
is considered to have the same synthetic pathway, activity, metabolism and clearance as ADMA but is present in only 10% of the concentration
Lambden et al. Critical Care          (2018) 22:336 Page 3 of 9
PCR technique known as Kompetitive Allele Specific
(KASP) PCR genotyping system which has been exten-
sively used for uniplex SNP analysis [37, 38]. Additional
quality-control criteria included interplate and intraplate
duplicate testing and clear separation of signal clusters.
Statistical analysis was performed using the Prism soft-
ware package (GraphPad Inc., CA, USA) and SPSS v25
(IBM plc, USA). Normally distributed data were analysed
using the t test or analysis of variance (ANOVA) with
Bonferroni post-test comparison of groups as appropri-
ate. Non parametric data were analysed using the
Mann-Whitney U test to compare two groups or
Kruskall-Wallis analysis for multiple groups, with Dunn’s
multiple comparison test undertaken to compare differ-
ences between the groups. Survival was analysed by the
log rank test to determine mortality trends and multi-
variate Cox regression analysis was undertaken to con-
sider potential for confounding by other clinical factors.
Results
Clinical population
Of the 408 patients included in the VANISH trial modi-
fied intention-to-treat analysis, 209 had buffy-coat sam-
ples and 75 had whole blood stored that was suitable for
DNA extraction and genotype analysis. In 249 of those
patients, at least one plasma sample was available for
analysis of methylarginine and L-arginine concentra-
tions. Peak methylarginine concentrations were defined
as the highest value measured from available samples for
each patient. In patients who did not survive for the full
sample collection period, the peak value from the avail-
able timepoints was selected. Patients in this subgroup
had similar baseline characteristics to those of the VAN-
ISH population as a whole and as there was no differ-
ence in the primary outcome of renal-failure-free days
or mortality between the treatment groups in the VAN-
ISH trial, all patients were analysed together in this
study (Additional file 1) [34]. In the population that
underwent genotyping analysis, median (IQR) duration
of shock was 47.5 (26.1–87.5) h.
Temporal pattern of L-Arginine and methylarginines in
septic shock
Plasma L-arginine and methylarginine concentrations
were measured at each available time point and temporal
patterns analysed (Table 1). Median L-arginine
concentration was at its lowest on study inclusion
then rose over subsequent study days (Fig. 2a).
ADMA concentrations were elevated over normal
plasma values [39] and median plasma ADMA con-
centration increased over the course of the study
period (p < 0.001) and was significantly higher on days
5 and 7 than at study inclusion (all p < 0.05, (Fig. 2b).
No significant changes in plasma SDMA concentra-
tion were observed during the study period, p = 0.478
(Additional file 1: Figure S1A).
The impact of treatment group allocation on L-arginine
and methylarginine concentrations was determined in
order to rule out any treatment group effect. No
differences were detected in plasma L-arginine or
methylarginine concentrations across treatment alloca-
tions (Additional file 1: Table S1).
L-arginine and methylarginine concentrations and
outcome
Median (IQR) L-arginine concentrations were similar in
both survivors and non-survivors at recruitment and on
day 3. A pattern of higher L-arginine concentration was,
however, associated with non-survivors on days 5 and 7
(Additional file 1: Table S2, Figure S1B).
Plasma concentrations of ADMA and SDMA were ele-
vated at each time point in patients who died compared
to survivors (Additional file 1: Table S3 and S4, Figure
S1C and S1D, respectively). Peak ADMA and SDMA
levels were also elevated in non-survivors (2.73 (2.14–
3.52) μM vs 1.98 (1.45–2.64) μM, p < 0.001 and 2.727
(2.14–3.52) μM vs 1.98 (1.45–2.64) μM), p < 0.001), re-
spectively. The area under the receiver operating charac-
teristic curve (SE) for peak ADMA concentration over
the study period was 0.705 (0.63–0.78) ) (p < 0.001) and
for SDMA it was 0.641 (0.56–0.73) (p < 0.001). The sur-
vival analysis showed that mortality rates increased with
increasing concentrations of ADMA and SDMA (Fig. 2c
and d, both p < 0.001). ADMA concentration in the
upper 50% of values was independently associated with
mortality in multivariate analysis including SDMA, age,
sex, L-arginine and serum creatinine concentration as
covariates (hazard ratio 1.82 (1.05–3.14), p = 0.033)
(Table 2). The ADMA:arginine ratio displayed a similar
pattern in the time course studied, with an increased ra-
tio seen on day 3 (p = 0.004) and a similar trend on day
7 (p = 0.20). (Additional file 1: Figure S1E).
Table 1 Pattern of plasma L-arginine, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) concentrations
(μM, median (IQR)) over the first 7 days of the VANISH trial
Inclusion Day 3 Day 5 Day7
L-arginine 25.3 (17.2–35.1) 30.0 (22.8–42.4) 32.6 (25.2–47.5) 32.9 (24.2–47.3)
ADMA 1.6 (1.17–2.2) 1.8 (1.3–2.4) 2.0 (1.6–2.7) 2.2 (1.6–2.8)
SDMA 3.4 (2.0–5.2) 3.4 (1.8–5.3) 3.4 (2.0–5.2) 3.1 (1.7–4.8)
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The impact of the rs805305 and eight DDAH1 SNP
polymorphisms on outcome in septic shock
The plasma ADMA concentration was corrected for
SDMA concentration as a marker of global DDAH activ-
ity. Lower DDAH activity was associated with improved
survival on log rank analysis (p = 0.033) (Fig. 3a).
The rs805305 SNP of the DDAH2 promoter region
was genotyped. The C:C genotype was seen in 128
(44.7%); the C:G heterozygote in 112 (39.1%) and the
homozygote G:G haplotype in 40 (13.9%) The G minor
allele of the rs805305 SNP was associated with signifi-
cantly lower 28-day mortality (31% in the common
wild-type C:C genotype, 22% in the C:G heterozygotes
and 15% in the less common G:G group, p = 0.02)
(Fig. 3b). Mean Sequential Organ Failure Assessment
(SOFA) score during the study period was significantly
reduced in patients with the G:G genotype (median
(IQR) 4.1 (3.25–5.8)) compared to the heterogozygotes
(5.0 (3.4–7.2)) and the common C:C genotype (5.2 (3.8–
7.7), p = 0.04) (Fig. 3c). ANOVA revealed that duration
of shock was also reduced in the G:G genotype (37 (23–
79) h) compared to 46 (23–76) h in C:G heterozygotes
and 53 (32–109) h in C:C genotype patients (p = 0.02)
(Fig. 3d). Hospital length of stay displayed a similar pat-
tern, with length of stay of 15.0 (11.0–47.0), 17 (8.25–
35.0) and 19 (8.75–40.5) days in the G:G, C:G and C:C
groups respectively, although this trend was not statisti-
cally significant (Additional file 1: Figure S2). The
plasma ADMA:SDMA ratio was also examined in pa-
tients with each of the three genotypes of the rs805305
SNP. In the less common G:G homozygotes the median
(IQR) ADMA:SDMA ratio was 1.0 (0.69–1.96), in the
Fig. 2 Temporal patterns in L-arginine and methylarginines over time in septic shock. Plasma L-arginine (a), asymmetric dimethylarginine (ADMA)
(b) concentration changes over the first 7 days of inclusion in the VANISH trial; notation describes the number of samples available for analysis at
each time point. Median and interquartile range plotted in red (both p < 0.001 over the time course (analysis of variance). Kaplan-Meier analysis of
the association between methylarginine concentrations and outcome over time in septic shock following inclusion in the VANISH trial. A higher
peak plasma ADMA (c) and symmetric dimethylarginine (SDMA) (d) concentration is associated with reduced survival in patients with
septic shock. Data presented in quartiles (black line - top 25%, small-dotted grey line - 2nd quartile, dashed grey line - 3rd quartile, solid
grey line - lowest quartile)
Table 2 Asymmetric and symmetric dimethylarginine, L-Arginine
and mortality - Cox regression
Univariate P value Multivariate P value
ADMA 3.3 (2.0–5.4) < 0.001 1.82 (1.05–3.14) 0.033
SDMA 2.25 (1.35–3.74) < 0.001 1.75 (0.95–3.20) 0.071
Age 2.24 (1.36–3.70) 0.002 1.80 (1.07–3.04) 0.027
Female sex 1.088 (0.66–1.79) 0.739 1.20 (0.71–2.05) 0.499
L-Arginine 1.316 (0.80–2.2) 0.283 1.07 (0.60–1.90) 0.812
Creatinine 2.13 (1.28–3.36) 0.004 1.56 (0.87–2.78) 0.14
Patients in the upper two quartiles of L-arginine, asymmetric dimethylarginine
(ADMA) and symmetric dimethylarginine (SDMA) concentrations were compared
to patients in the lower quartiles. Patients in the upper quartile of age and serum
creatinine were compared to those in the lowest three quartiles
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C:G heterozygotes it was 0.68 (0.51–0.95) and in the
common C:C genotype it was 0.64 (0.40–0.91) (p =
0.004) (Additional file 1: Figure S3). Homozygotes for
the less common DDAH1 SNPs genotyped were found
in approximately 1% of the study population. No associ-
ation with outcome was observed when the risk of death
for those expressing the common homozygote genotype
was compared to a combined group of heterozygotes
and rare homozygotes of each SNP (Additional file 1:
Table S5).
Discussion
This study validates in septic shock the observation
made in heterogeneous groups with sepsis that elevated
plasma ADMA concentration is associated with out-
come. In addition, for the first time, we make the obser-
vation that a promoter polymorphism of the DDAH2
gene, rs805305 is associated with reduced DDAH activ-
ity, and in turn improved outcomes in septic shock.
The role of NO in the progression of the inflammatory
response in patients with sepsis is complex, with essential
upregulation of NO production facilitating appropriate
vascular, cardiac and immune responses to pathogenic in-
vasion. However, dysregulation of NO synthesis is a car-
dinal feature of septic shock and understanding how
endogenous inhibitors of NOS enzymes and the genes
that regulate them contribute to outcome in sepsis offers
the potential for risk stratification and therapeutic devel-
opment in an area of considerable unmet clinical need.
This is the largest study undertaken to date of methy-
larginine and L-arginine flux in septic shock and builds
on previous work associating ADMA concentrations
with outcome. By including only patients with estab-
lished septic shock in this study, we were able to limit
the heterogeneity seen in other studies in which sepsis
and severe sepsis diagnoses were also included.
Our findings confirm the observations of a meta-ana-
lysis of 192 patients with sepsis, which concluded that
L-arginine concentration is significantly reduced in the
first week of a septic insult [40], which may be an im-
portant anti-inflammatory mechanism and increases the
impact of competitive inhibitors of NOS on NO synthe-
sis. We also validated the observation from heteroge-
neous sepsis cohorts [19, 21, 41] that in sepsis, both
Fig. 3 Associations between the rs805305 SNP of the dimethylarginine dimethylaminohydrolase (DDAH)2 promoter region and DDAH activity and
outcome in septic shock. a Lower DDAH activity is associated with improved outcome in septic shock. Asymmetric dimethylarginine (ADMA):symmetric
dimethylarginine (SDMA) ratio was employed as a marker of DDAH activity. Black line - patients with the lowest activity, dotted grey line - 2nd quartile,
dashed grey line - 3rd Quartile, solid grey line – highest-activity quartile. The rs805305 SNP of the promoter region of the DDAH2 gene was sequenced in
284 participants in the VANISH trial. b Kaplan-Meier analysis of the impact of rs805305 SNP on 28-day survival in septic shock. The presence of the rare G:G
homozygote (13.9%) was associated with improved survival compared to the common C:C homozygote (44.7), p= 0.02. Mean Sequential Organ Failure
Assessment (SOFA) score (c) and shock duration (d) were lower in patients expressing the less common G:G genotype than the common C:C expression
pattern, p= 0.04 and p = 0.02, respectively (analysis of variance)
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plasma ADMA and SDMA are associated with poor out-
come, with similar degrees of sensitivity and specificity.
The relationship between arginine and ADMA concentra-
tions has been proposed as a marker of NOS activity in
vivo [23]. Increased ADMA concentrations coupled with
reductions in arginine availability in sepsis change the re-
lationship between substrate and competitive inhibitor
concentrations leading to reductions in NO production.
In this study we found that survivors may have had lower
NOS activity after day 3 than those patients that did not
survive to discharge from the ICU. This may be consistent
with reduced severity of NO-mediated inflammatory re-
sponse, and is predominantly driven by reductions in
plasma L-arginine concentrations. The factors that regu-
late L-arginine availability are important regulators of the
inflammatory response and merit further exploration in
septic shock.
These data suggest for the first time in a robust hu-
man population with septic shock that an increased
ADMA:SDMA ratio is associated with increased sur-
vival. This builds on animal and human data suggesting
that the plasma ADMA:SDMA ratio may be a better re-
flection of DDAH enzyme activity than ADMA concen-
tration alone [42, 43]. This reflects the observation that
using the circulating ADMA concentration as a marker
of DDAH activity is confounded by changes in protein
turnover and renal function in acute disease states. Cor-
recting ADMA for SDMA concentration may eliminate
this confounder because SDMA handling will be simi-
larly affected by protein turnover and renal failure. Since
it is not metabolised by DDAH isoforms, any changes in
the relative proportions of ADMA and SDMA is likely
to be driven by changes in DDAH activity.
This study shows that in those patients with lower
DDAH activity, the resultant increased intracellular
ADMA concentrations may confer a survival advantage
during an acute disease process such as sepsis by modulat-
ing the acute production of excess NO. This is in contrast
to plasma ADMA measurement alone and also may re-
flect a different physiological effect of ADMA in sepsis to
that seen in chronic disease states where persistent eleva-
tion of intracellular ADMA may be deleterious [44–46].
Previous transgenic animal models have suggested that
global and macrophage-specific knockout DDAH2 is asso-
ciated with poor outcomes in murine models of sepsis
[35]. This contrasts with the observations in this study
and may reflect the difference between the complete abo-
lition of DDAH2 activity seen in knockout models com-
pared to the modulation of enzyme activity typically seen
with functional polymorphisms.
The rs805305 SNP has been examined in pilot studies
in sepsis and been associated with plasma ADMA and
inflammatory cytokine expression [19, 21, 41]. It has also
been associated with the development of hypertension in
other populations [47]. Here we show for the first time
that the rs805305 SNP is associated with reduced DDAH
activity and survival in septic shock. This small study of
a genetic association with outcome in septic shock offers
insights into the role of endogenous regulators of NO
synthesis. Future work will focus on validating this ob-
servation and understanding the potential for DDAH2
modulation as therapy in septic shock.
Limitations of this study include a possible bias intro-
duced by using patients included in a randomised con-
trolled trial. The use of results, plasma and DNA from
the VANISH trial enabled high-quality data collection in
multiple centres that does, however, confer a significant
advantage in translational studies of this kind over small,
single-centre observational studies. The combination of
approaches utilised in this study gives confidence in its
conclusions; however, further validation of the role of
the rs805305 polymorphism in septic shock in a further
data set would be valuable.
Future work should focus on the potential effect of
therapeutic modulation of DDAH activity as a whole
and DDAH2 specifically merits exploration in septic
shock, with the ADMA:SDMA ratio offering an attract-
ive marker of therapeutic efficacy [31].
Conclusions
In conclusion, this study is the largest yet conducted ex-
ploring the associations between DDAH activity and
outcome in septic shock. We confirmed the observation
that both plasma ADMA and SDMA are associated with
outcome. We showed for the first time using the
ADMA:SDMA ratio that reduced DDAH activity is asso-
ciated with improved survival and that the rs805305
SNP of the DDAH2 promoter region is associated with
both reduced DDAH activity and improved survival.
Additional file
Additional file 1: Table S1. Median (IQR) peak concentrations of L-
arginine, ADMA and SDMA (μM) in patients with septic shock categorised
by treatment arm in the VANISH trial; p value for Kruskall-Wallis test, no
intergroup differences detected on Dunn’s multiple comparison testing.
Table S2. Pattern of plasma L-arginine concentrations over the first 7 days
of the VANISH trial in survivors and non-survivors. Median (IQR)
concentrations (μM). Table S3. Pattern of plasma ADMA concentrations
over the first 7 days of the VANISH trial in survivors and non-survivors.
Median (IQR) concentrations (μM). Table S4. Pattern of plasma SDMA
concentrations over the first 7 days of the VANISH trial in survivors and non-
survivors. Median (IQR) concentrations (μM). Table S5. Relationship between
eight intronic SNPs of DDAH1 and mortality in septic shock. The prevalence
of the rare genotype in each of the eight DDAH1 SNPs was noted. The odds
ratio of death at 28 days after study inclusion was calculated for the common
homozygotes against the combined heterozygote and rare homozygote
populations. No significant differences in outcome were observed between
the groups expressing the less common alleles and the common
homozygotes. Figure S1. Plasma concentrations of L-arginine (A),
ADMA (B) and SDMA (C) in septic shock and association with survival.
Plasma from 249 patients with septic shock enrolled in the VANISH trial was
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collected collection on inclusion into the trial, which was prior to the start
of vasopressor therapy (Day 0), and on days 3, 5 and 7 of the study. Dot
plot (with median (IQR) overlay in black (survivors) or red (non-survivors))
comparing plasma concentrations on study inclusion and on days 3, 5 and
7 after study inclusion in survivors and non-survivors at 28 days after
admission with septic shock. Median (IQR) plasma L-arginine concentrations
were similar in non-survivors at each time point. Plasma ADMA and SDMA
concentrations were higher in non-survivors at each time point. D Plasma
SDMA concentration changes over the first 7 days of inclusion in the VAN-
ISH trial, notation describes the number of samples available for analysis at
each time point. Median and interquartile range plotted in red. E Dot plot
(with median (IQR) overlay in black (survivors) or red (non-survivors))
comparing plasma ADMA:L-arginine concentrations on study inclusion and
on days 3, 5 and 7 after study inclusion in survivors and non-survivors at 28
days after admission with septic shock. Median (IQR) plasma ADMA:L-
arginine concentrations appeared higher in non-survivors at days 3,5 and 7.
Figure S2. Association between the rs805305 SNP of the DDAH2 promoter
region and outcome in septic shock. Presence of the rare G:G homozygote
was associated with a trend towards reduced hospital length of stay but
was not statistically significant. Figure S3. Association between the
rs805305 SNP of the DDAH2 promoter region and DDAH activity and
outcome in septic shock. Plasma ADMA:SDMA ratio was elevated in the rare
G:G genotype compared to the common C:C expression pattern, p = 0.004.
(DOCX 3485 kb)
Abbreviations
ADMA: Asymmetric dimethylarginine; ANOVA: Analysis of variance;
DDAH: Dimethylarginine dimethylaminohydrolase; IQR: Interquartile range;
KASP: Kompetitive allele specific; LNMMA: Monomethylarginine;
MA: Methylarginine; NO: Nitric oxide; NOS: Nitric oxide synthase;
SDMA: Symmetric dimethylarginine; SNP: Single nucleotide polymorphism;
SOFA: Sequential Organ Failure Assessment; VANISH: Vasopressin versus
noradrenaline as initial therapy in septic shock
Acknowledgements
The authors would like to acknowledge the recruitment sites for their efforts
in collecting and preparing samples for the subsequent analysis and the
research team at Imperial College NHS trust for their support in the conduct
of this study.
Funding
This VANISH trial was funded by the UK National Institute for Health Research
(NIHR) under its Research for Patient Benefit programme (grant number PB-PG-
0610-22,350) and an NIHR Clinician Scientist Award held by Dr. Gordon.
Infrastructure support was provided by the NIHR Imperial Biomedical
Research Centre. MRC intramurual funding, BJA/RCoA NIAA project grant.
ACG is an NIHR Research Professor. SL is an NIHR Clinical Lecturer.
Availability of data and materials
Data are available in an online supplement.
Authors’ contributions
SL participated in the design of the study, prepared samples for genotype
analysis, performed measurements of NOx and methylarginine levels in
biological samples and performed statistical analysis. SP and JT performed
measurements of methyarginines in biological samples. AG and JL conceived
the study and participated in the study design, interpretation of results and
drafting of the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The study received ethics committee approval (Oxford A research ethics
committee (12/SC/0014)) and was registered prior to the start of recruitment
(ISRCTN20769191).
Consent for publication
Patient consent was secured for participation in this study and publication of
relevant results.
Competing interests
JL and SL are founding directors of and consultants to Critical Pressure ltd.
ACG reports that outside of this work he has received speaker fees from
Orion Corporation Orion Pharma and Amomed Pharma. He has consulted
for Ferring Pharmaceuticals, Tenax Therapeutics, Baxter Healthcare, Bristol-
Myers Squibb and GSK and received grant support from Orion Corporation
Orion Pharma, Tenax Therapeutics and HCA International with funds paid to
his institution.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Department of Medicine, University of Cambridge, Addenbrooke’s Hospital,
Cambridge CB2OQQ, UK. 2Institute of Cardiovascular and Medical Sciences,
University of Glasgow, University Avenue, Glasgow G12 8QQ, UK. 3MRC
London Institute of Medical Sciences, Hammersmith Hospital Campus, Du
Cane Road, London W12 0NN, UK. 4Section of Anaesthetics, Pain Medicine
and Intensive Care, Faculty of Medicine, Imperial College London, London,
UK.
Received: 31 July 2018 Accepted: 26 November 2018
References
1. Marshall JC. Sepsis: rethinking the approach to clinical research. J Leukoc
Biol. 2008;83:471–82.
2. Shankar-Hari M, Bertolini G, Brunkhorst FM, Bellomo R, Annane D,
Deutschman CS, Singer M. Judging quality of current septic shock
definitions and criteria. Crit Care. 2015;19:1–5.
3. Vincent JL, Backer D. Circulatory shock. N Engl J Med. 2013;369:1726–34.
4. Vincent JL, Gris P, Coffernils M, Leon M, Pinsky M, Reuse C. Myocardial
depression characterizes the fatal course of septic shock. Surgery. 1992;111:
660–7.
5. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak
GM, Buchman TG, Karl IE. Apoptotic cell death in patients with sepsis, shock,
and multiple organ dysfunction. Crit Care Med. 1999;27:1230–51.
6. De Backer D, Creteur J, Preiser J-C, Dubois M-J, Vincent J-L. Microvascular
blood flow is altered in patients with sepsis. Am J Respir Crit Care Med.
2002;166:98–104.
7. Lagu T, Rothberg MB, Shieh M-S, Pekow PS, Steingrub JS, Lindenauer PK.
What is the best method for estimating the burden of severe sepsis in the
United States? J Crit Care. 2012;27:414.e1–9.
8. Fleischmann C, Scherag A, Adhikari NKJ, Hartog CS, Tsaganos T,
Schlattmann P, Angus DC, Reinhart K. Assessment of global incidence and
mortality of hospital-treated sepsis. Current estimates and limitations. Am J
Respir Crit Care Med. 2015;193:259–72.
9. Arnalich F, Hernanz A, Jiménez M, López J, Tato E, Vázquez JJ, Montiel C.
Relationship between circulating levels of calcitonin gene-related peptide,
nitric oxide metabolites and hemodynamic changes in human septic shock.
Regul Pept. 1996;65:115–21.
10. Cauwels A. Ntric Oxide in septic shock. Kidney Int. 2007;72:557–65.
11. Endo S, Inada K, Nakae H, Arakawa N, Takakuwa T, Yamada Y, Shimamura T,
Suzuki T, Taniguchi S, Yoshida M. Nitrite/nitrate oxide (NOx) and cytokine
levels in patients with septic shock. Res Commun Mol Pathol Pharmacol.
1996;91:347–56.
12. Lopez A, Lorente J, Steingrub J, Bakker J, McLuckie A, Willatts S,
Brockway M, Anzueto A, Holzapfel L, Breen D. Multiple-center,
randomized, placebo-controlled, double-blind study of the nitric oxide
synthase inhibitor 546C88: effect on survival in patients with septic
shock. Crit Care Med. 2004;32:21–30.
13. Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. J Biol Chem.
1994;269:13725–8.
14. Leone A, Moncada S, Vallance P, Calver A, Collier J. Accumulation of an
endogenous inhibitor of nitric oxide synthesis in chronic renal failure.
Lancet. 1992;339:572–5.
15. McBride AE, Silver PA. State of the Arg: protein methylation at arginine
comes of age. Cell. 2001;106:5–8.
16. Meyer J, Richter N, Hecker M. High-performance liquid chromatographic
determination of nitric oxide synthase-related arginine derivatives in vitro
and in vivo. Anal Biochem. 1997;247:11–6.
Lambden et al. Critical Care          (2018) 22:336 Page 8 of 9
17. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-
Klein C, Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Münzel T.
Asymmetric dimethylarginine and the risk of cardiovascular events and
death in patients with coronary artery disease: results from the AtheroGene
Study. Circ Res. 2005;97:e53–9.
18. Caplin B, Nitsch D, Gill H, Hoefield R, Blackwell S, MacKenzie D, Cooper JA,
Middleton RJ, Talmud PJ, Veitch P, Norman J, Wheeler DC, Leiper JM.
Circulating methylarginine levels and the decline in renal function in
patients with chronic kidney disease are modulated by DDAH1
polymorphisms. Kidney Int. 2009;77:459–67.
19. O'Dwyer M, Dempsey F, Crowley V, Kelleher D, McManus R, Ryan T. Septic
shock is correlated with asymmetrical dimethyl arginine levels, which may
be influenced by a polymorphism in the dimethylarginine
dimethylaminohydrolase II gene: a prospective observational study. Crit
Care. 2006;10:R139.
20. Tea B. L-arginine and asymmetric dimethylarginine are early predictors for survival
in septic patients with acute liver failure. Mediators Inflamm. 2012;2012:11.
21. Davis JS, Darcy CJ, Yeo TW, Jones C, McNeil YR, Stephens DP, Celermajer DS,
Anstey NM. Asymmetric dimethylarginine, endothelial nitric oxide
bioavailability and mortality in sepsis. PLoS One. 2011;6:e17260.
22. Mortensen KM, Itenov TS, Haase N, Müller RB, Ostrowski SR, Johansson PI,
Olsen NV, Perner A, Søe-Jensen P, Bestle MH. High levels of methylarginines
were associated with increased mortality in patients with severe sepsis.
Shock. 2016;46:365–72.
23. Winkler MS, Kluge S, Holzmann M, Moritz E, Robbe L, Bauer A, Zahrte C,
Priefler M, Schwedhelm E, Böger RH, Goetz AE, Nierhaus A, Zoellner C.
Markers of nitric oxide are associated with sepsis severity: an observational
study. Crit Care. 2017;21:189.
24. Leiper JM. Identification of two human dimethylarginine
dimethylaminohydrolases with distinct tissue distributions and homology
with microbial arginine deiminases. Biochem J. 1999;343:209–14.
25. Tran CT, Fox MF, Vallance P, Leiper JM. Chromosomal localization, gene
structure, and expression pattern of DDAH1: comparison with DDAH2 and
implications for evolutionary origins. Genomics. 2000;68:101–5.
26. Tran CTL, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway.
Atheroscler Suppl. 2003;4:33–40.
27. Seoa H-A, Kima S-W, Jeona E-J, Jeonga J-Y, Moonb S-S, Leed W-K, Kima J-G,
Leea c I-K, Park K-G. Association of the DDAH2 gene polymorphism with
type 2 diabetes and hypertension. Diabetes Res Clin Pract. 2012;98:125–31.
28. Pérez-Hernández N, Vargas-Alarcón G, Arellano-Zapoteco R, Martínez-
Rodríguez N, Fragoso JM, Aptilon-Duque G, Posadas-Sánchez R, Posadas-
Romero C, Juárez-Cedillo T, Domínguez-López ML, Rodríguez-Pérez JM.
Protective role of DDAH2 (rs805304) gene polymorphism in patients with
myocardial infarction. Exp Mol Pathol. 2014;97:393–8.
29. Marra M, Marchegiani F, Ceriello A, Sirolla C, Boemi M, Franceschi C,
Spazzafumo L, Testa I, Bonfigli AR, Cucchi M, Testa R. Chronic renal
impairment and DDAH2-1151 A/C polymorphism determine ADMA levels in
type 2 diabetic subjects. Nephrol Dial Transplant. 2013;28:964–71.
30. Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O’Hara B, Rossiter S,
Anthony S, Vallance P. Disruption of methylarginine metabolism impairs
vascular homeostasis. Nat Med. 2007;13:198–203.
31. Wang Z, Lambden S, Taylor V, Sujkovic E, Nandi M, Tomlinson J, Dyson A,
McDonald N, Caddick S, Singer M, Leiper J. Pharmacological inhibition of
DDAH1 improves survival, hemodynamics and organ function in
experimental septic shock. Bichem J. 2014;460:309–16.
32. Lambden S, Martin D, Tomlinson J, Mythen M, Leiper J. Role of
dimethylarginine dimethylaminohydrolase 2 in the regulation of nitric oxide
synthesis in animal and observational human models of normobaric
hypoxia. Lancet. 2016;387:S62.
33. Gordon AC, Mason AJ, Perkins GD, Ashby D, Brett SJ. Protocol for a
randomised controlled trial of vasopressin versus noradrenaline as initial
therapy in septic shock (VANISH). BMJ Open. 2014;4:e005866.
34. Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of early vasopressin
vs norepinephrine on kidney failure in patients with septic shock: the vanish
randomized clinical trial. JAMA. 2016;316:509–18.
35. Lambden S, Kelly P, Ahmetaj-Shala B, Wang Z, Lee B, Nandi M, Torondel B,
Delahaye M, Dowsett L, Piper S, Tomlinson J, Caplin B, Colman L, Boruc O,
Slaviero A, Zhao L, Oliver E, Khadayate S, Singer M, Arrigoni F, Leiper J.
Dimethylarginine dimethylaminohydrolase 2 regulates nitric oxide synthesis
and hemodynamics and determines outcome in polymicrobial sepsis.
Arterioscler Thromb Vasc Biol. 2015;35:1382–92.
36. Tomlinson JAP, Caplin B, Boruc O, Bruce-Cobbold C, Cutillas P, Dormann D,
Faull P, Grossman RC, Khadayate S, Mas VR, Nitsch DD, Wang Z, Norman JT,
Wilcox CS, Wheeler DC, Leiper J. Reduced renal methylarginine metabolism
protects against progressive kidney damage. JASN. 2015;26(12):3045–59.
37. Semagn K, Babu R, Hearne S, Olsen M. Single nucleotide polymorphism
genotyping using Kompetitive Allele Specific PCR (KASP): overview of the
technology and its application in crop improvement. Mol Breed. 2013;33:1–14.
38. Levinsson A, Olin A-C, Björck L, Rosengren A, Nyberg F. Nitric oxide
synthase (NOS) single nucleotide polymorphisms are associated with
coronary heart disease and hypertension in the INTERGENE study. Nitric
Oxide. 2014;39:1–7.
39. Leiper J, Vallance P. Biological significance of endogenous methylarginines
that inhibit nitric oxide synthases. Cardiovasc Res. 1999;43:542–8.
40. Davis JS, Anstey NM. Is plasma arginine concentration decreased in patients
with sepsis? A systematic review and meta-analysis. Crit Care Med. 2011;39:
380–5.
41. Weiss SL, Haymond S, Ranaivo HR, Wang D, De Jesus VR, Chace DH,
Wainwright MS. Evaluation of asymmetric dimethylarginine, arginine, and
carnitine metabolism in pediatric sepsis. Paediatr Crit Care Med. 2012;13:
e210–8.
42. Umbrello M, Pavini FC, Bolgiaghi L, Carloni E, Rapido F, Gomarasca M,
D'Angelo E, Iapichino G. Asymmetric and symmetric dimethylarginines:
metabolism and role in severe sepsis. Crit Care. 2009;13:P361.
43. Carello KA, Whitesall SE, Lloyd MC, Billecke SS, D'Alecy LG. Asymmetrical
dimethylarginine plasma clearance persists after acute total nephrectomy in
rats. Am J Physiol Heart Circ Physiol. 2006;290:H209–16.
44. Boger R. Asymmetric dimethylarginine (ADMA): a novel risk marker in
cardiovascular medicine and beyond. Ann Med. 2006;38:126–36.
45. Böger RH, Endres HG, Schwedhelm E, Darius H, Atzler D, Lüneburg N, von
Stritzky B, Maas R, Thiem U, Benndorf RA, Diehm C. Asymmetric
dimethylarginine as an independent risk marker for mortality in ambulatory
patients with peripheral arterial disease. J Intern Med. 2011;269:349–61.
46. Willeit P, Freitag DF, Laukkanen JA, Chowdhury S, Gobin R, Mayr M, Di
Angelantonio E, Chowdhury R. Asymmetric dimethylarginine and
cardiovascular risk: systematic review and meta-analysis of 22 prospective
studies. J Am Heart Assoc. 2015;4:e001833.
47. Maas R, Erdmann J, Lüneburg N, Stritzke J, Schwedhelm E, Meisinger C,
Peters A, Weil J, Schunkert H, Böger RH, Lieb W. Polymorphisms in the
promoter region of the dimethylarginine dimethylaminohydrolase 2 gene
are associated with prevalence of hypertension. Pharmacol Res. 2009;60:
488–93.
Lambden et al. Critical Care          (2018) 22:336 Page 9 of 9
